COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00361166
Recruitment Status : Completed
First Posted : August 7, 2006
Last Update Posted : March 22, 2007
Information provided by:
ACADIA Pharmaceuticals Inc.

Brief Summary:

The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated. Further purposes of this study are to determine whether ACP-103, in combination with either haloperidol or risperidone, will enhance their antipsychotic effectiveness, demonstrate effectiveness against the negative symptoms, improve motoric tolerability, and is safe and well tolerated.

This is a seven-week study (one week screening and six weeks of study medication) where a total of 400 patients who meet entrance criteria will randomly be assigned to receive one of five groups of study treatments of either low dose haloperidol plus ACP-103, low dose haloperidol plus placebo (a substance similar to a sugar pill), low dose risperidone plus ACP-103, low dose risperidone plus placebo, or high dose risperidone plus placebo. The study will begin with with a three to seven day drug-free period followed by six weeks of a stable daily dosage of study medication. Study subjects will be treated as hospital in-patients during screening and for the first 14 days of the study. Study subjects will be closely monitored throughout the study.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: ACP-103 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects
Study Start Date : August 2005
Actual Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Primary Outcome Measures :
  1. Total score on the Positive and Negative Symptom Scale (PANSS).

Secondary Outcome Measures :
  1. Clinical Global Impression-Severity (CGI-S), Simpson Angus Scale (SAS), Barnes Akathisia Scale (BAS), Calgary Depression Scale for Schizophrenia (CDSS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male or female subjects ages 18-65 diagnosed with schizophrenia
  • experiencing an acute exacerbation of psychosis
  • has had prior response to antipsychotic therapy within the previous 3 years
  • female subjects must be of non-childbearing potential or must comply with double-barrier protection methods against conception
  • ability of subject or caregiver or legally authorized representative to provide informed consent
  • subjects must be hospitalized at screening and must be willing to remain in the hospital at least 14 days after baseline and must comply with all study events through completion of the study

Exclusion Criteria:

  • inability of the subject or caregiver or legally authorized representative to provide consent
  • any female subject who is pregnant or breast feeding
  • any subject with concurrent mental illness or disability
  • any subject considered to be a danger to themselves or others
  • recent use of certain antipsychotics or other medications that might interfere with this study's medication
  • abnormal clinical laboratory values
  • presence, or recent history, of serious medical conditions or drug abuse
  • likely allergy or sensitivity to ACP-103, haloperidol, or risperidone, based on known allergies to drugs of the same class
  • any subject who has participated in a prior clinical trial of ACP-103
  • any subject judged by the Principal Investigator to be inappropriate for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00361166

Layout table for location information
United States, California
Cerritos, California, United States, 90703
Garden Grove, California, United States, 92845
Glendale, California, United States, 91206
Paramount, California, United States, 90723
Pico Rivera, California, United States, 90660
San Diego, California, United States, 92123
San Diego, California, United States, 92126
United States, District of Columbia
Washington, District of Columbia, United States, 20016
United States, Missouri
St. Louis, Missouri, United States, 63118
United States, Texas
Austin, Texas, United States, 78756
Irving, Texas, United States, 75062
Salvador, BA, Brazil, 40325-090
Aparecida de Goiânia, GO, Brazil, 74922-810
Curitiba, PR, Brazil, 80430-050
Curitiba, PR, Brazil, 80520-000
Rio de Janeiro, RJ, Brazil, 21020-130
São Paulo, SP, Brazil, 05403-010
Sponsors and Collaborators
ACADIA Pharmaceuticals Inc.
Layout table for investigator information
Study Chair: Daniel van Kammen, MD, PhD ACADIA Pharmaceuticals Inc.
Layout table for additonal information Identifier: NCT00361166    
Other Study ID Numbers: ACP-103-008
First Posted: August 7, 2006    Key Record Dates
Last Update Posted: March 22, 2007
Last Verified: March 2007
Keywords provided by ACADIA Pharmaceuticals Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antiparkinson Agents
Anti-Dyskinesia Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action